Encorafenib is an oral BRAF inhibitor that inhibits tumor growth by targeting abnormally activated kinases such as BRAF V600E and blocking the RAS/RAF/MEK/ERK proliferation signaling pathway.
Mechanism of Action
BRAF is a critical node in the MAPK signaling pathway (RAS → RAF → MEK → ERK). Mutations like BRAF V600E keep this node continuously activated, instructing cells to proliferate incessantly without requiring upstream signals.
Encorafenib inhibits the kinase activity of BRAF V600E, wild-type BRAF, and CRAF, with in vitro IC50 values of 0.35 nM, 0.47 nM, and 0.3 nM, respectively.
In vitro, it inhibits the growth of tumor cell lines harboring BRAF V600E, V600D, and V600K mutations. In mouse xenograft models bearing BRAF V600E tumor cells, encorafenib induces tumor regression accompanied by suppression of the RAF/MEK/ERK pathway.
Combination Regimens
1. Rationale for Combination with Binimetinib
When used as a monotherapy, BRAF inhibitors may trigger feedback reactivation of the MAPK pathway through the ERK pathway. Binimetinib is a MEK inhibitor acting downstream of BRAF; combining both blocks the signaling pathway at two distinct points.
2. Rationale for Combination with Cetuximab
In BRAF-mutated colorectal cancer, EGFR-mediated activation of the MAPK pathway is considered a mechanism of resistance to BRAF inhibitors. Combining a BRAF inhibitor with an EGFR-targeted drug overcomes this resistance mechanism in non-clinical models. Cetuximab is an anti-EGFR monoclonal antibody designed for this target.
FDA-Approved Indications
1. Metastatic Non-Small Cell Lung Cancer (NSCLC)
Encorafenib in combination with binimetinib for the treatment of adult patients with metastatic non-small cell lung cancer harboring a BRAF V600E mutation.
2. Melanoma
Encorafenib in combination with binimetinib for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
3. Metastatic Colorectal Cancer (mCRC)
Encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer harboring a BRAF V600E mutation, after prior systemic therapy.
4. First-Line Treatment for Metastatic Colorectal Cancer in Combination with Chemotherapy
Encorafenib in combination with cetuximab and fluoropyrimidine-based chemotherapy (mFOLFOX6 or FOLFIRI) for adult patients with BRAF V600E-mutated metastatic colorectal cancer.
Time to Onset and Duration of Treatment
1. Time to Onset
For most patients, radiographic changes become visible within 1 to 2 months, though it may take longer for some individuals. Routine efficacy evaluations are typically scheduled using a 2 to 3-month imaging assessment window.
2. Duration of Treatment
Treatment continues until disease progression or unacceptable toxicity occurs.
Reminder: Encorafenib is a prescription medication. Dosages and treatment schedules must be determined by a medical oncologist. Do not adjust the dosage or discontinue treatment independently.
